Miraculins Appoints Pharmaceutical Executive David Howard to Board of Directors
News Mar 31, 2011
Miraculins Inc. has announced that it has appointed experienced pharmaceutical executive Mr. David Howard to its Board of Directors.
David Howard is currently the Chairman of Angiotech, a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products.
The Company's lead product, the TAXUS® drug-eluting coronary stent - which was co-developed with and is now sold by Boston Scientific Corporation - is implanted in over five million patients worldwide. Mr. Howard is also a director of Via Pharmaceuticals Inc., Bioasis Technologies Inc, and Methylation Sciences Inc.
Mr. Howard's distinguished career also includes leadership of SCOLR, Inc., a biopharmaceutical company located in Redmond, WA where he held the offices of CEO and Chairman of the Board. Prior to this, he served as President and Chief Operating Officer of Novopharm International Inc. , and President of both Novopharm USA, Inc. and Stanley Pharmaceuticals Inc.
Mr. Howard's industry experience includes operational and strategic positions with Boehringer Mannheim Canada, where he was Vice President, Pharmaceuticals Division and Rhone-Poulenc Pharma, in Montreal and Paris, where he held critical positions in International Product Management, International Licensing & Agreements, and International Zone Management for the Nordic Region and SE Asia.
Mr. Howard is a graduate of the University of Saskatchewan and the Rotman School of Management and the Sauder School of Business in their Director education Programs.
"We are pleased with David's acceptance of our invitation to join the Miraculins Board of Directors, bringing with him a depth of experience in technology development, commercialization, partnering and governance", commented Dr. Albert Friesen, Chairman of Miraculins Inc. "His guidance will be of great importance to Miraculins as we continue our growth phase, and work towards the commercialization of our medical device programs."
Upon his appointment to the Board of Directors, Miraculins has granted 100,000 stock options to Mr. Howard with an exercise price of $0.10 per common share. The options are set to expire five years from the date of grant and are subject to TSX Venture Exchange acceptance and the terms of Miraculins' stock option plan.
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn’t actually have schizophrenia. People who reported hearing voices or having anxiety were the ones more likely to be misdiagnosed.